ibandronic acid has been researched along with Osteonecrosis in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Matys, T | 1 |
| Acar, A; Çağlar, A; Çağlar, S; Çataltepe, A; Daşcı, MF; Dinçel, YM | 1 |
| Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T | 1 |
| Friederich, NF; Grize, L; Kraenzlin, C; Kraenzlin, ME; Meier, C; Meier, CR; Wischer, T | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Armonis, BN; Migliorati, CA; Nicolatou-Galitis, O | 1 |
| Mupparapu, M; Singer, SR | 1 |
| Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Guadagnini, JP; Gulley, JL; Latham, L; Ning, YM; Parnes, H; Wright, JJ | 1 |
| Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Bainton, R; Hindawi, M; Srinivasan, D | 1 |
| Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I | 1 |
| Pazianas, M | 1 |
| Amling, M; Barvencik, F; Breer, S; Krause, M; Marshall, RP; Oheim, R | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Malden, NJ; Pai, AY | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
5 review(s) available for ibandronic acid and Osteonecrosis
| Article | Year |
|---|---|
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
2 trial(s) available for ibandronic acid and Osteonecrosis
| Article | Year |
|---|---|
Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Double-Blind Method; Edema; Female; Follow-Up Studies; Humans; Ibandronic Acid; Knee Joint; Magnetic Resonance Imaging; Male; Middle Aged; Osteonecrosis; Pain Measurement; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidence; Jaw Diseases; Male; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Prostatic Neoplasms | 2009 |
15 other study(ies) available for ibandronic acid and Osteonecrosis
| Article | Year |
|---|---|
Medication-related Osteonecrosis of the Jaw.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Jaw; Osteonecrosis; Tomography, X-Ray Computed | 2021 |
Comparison of the prophylactic use of ibandronate and its use in early-stage osteonecrosis in rats with steroid-induced osteonecrosis of the femoral head.
Topics: Animals; Female; Femur Head; Ibandronic Acid; Osteonecrosis; Rats; Rats, Sprague-Dawley; Steroids; X-Ray Microtomography | 2023 |
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid | 2022 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis | 2008 |
Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diagnosis, Differential; Diphosphonates; Female; Humans; Ibandronic Acid; Maxillary Diseases; Osteonecrosis | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction | 2010 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Non-surgical management of stage 3 biphosphonate-related oroantral fistula.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Bone Density Conservation Agents; Clindamycin; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Hydrogen Peroxide; Ibandronic Acid; Maxillary Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Povidone-Iodine; Tooth Extraction | 2011 |
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid | 2010 |
Spontaneous osteonecrosis of the knee (SONK).
Topics: Administration, Intravenous; Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Female; Femur; Humans; Ibandronic Acid; Knee; Magnetic Resonance Imaging; Male; Middle Aged; Osteonecrosis; Vitamin D | 2013 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |